

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | |
|----------|--|---|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Baldur Sveinbjörnsson |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Scientific Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of issuer | |
| a) | Name | Lytix Biopharma AS |
| b) | LEI | 549300NXMIMRBCDZO71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) |
| b) | Nature of the transaction | Subscription and allocation of shares |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | NOK 6 |
| | | 8,333 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 8,333 Total price: NOK 49,998 |
| e) | Date of the transaction | 2024-12-16 |
| f) | Place of the transaction | Outside a trading venue |

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | |
|----------|--|---|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Evelina Wanda Matilda Vägesjö |
| 2 | Reason for the notification | |
| a) | Position/status | Board member |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of issuer | |
| a) | Name | Lytix Biopharma AS |
| b) | LEI | 549300NXMIMRBCDZO71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) |
| b) | Nature of the transaction | Subscription and allocation of shares |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | NOK 6 |
| | | 4,247 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 4,247 Total price: NOK 25,482 |
| e) | Date of the transaction | 2024-12-16 |
| f) | Place of the transaction | Outside a trading venue |

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Gjest Andreas Breistein |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of issuer | |
| a) | Name | Lytix Biopharma AS |
| b) | LEI | 549300NXMIMRSBCDZO71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) |
| b) | Nature of the transaction | Subscription and allocation of shares |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | NOK 6 |
| | | 16,666 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 16,666 Total price: NOK 99,996 |
| e) | Date of the transaction | 2024-12-16 |
| f) | Place of the transaction | Outside a trading venue |

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | | |
|----------|--|--|------------------|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | | |
| a) | Name | Kjetil Hestdal | |
| 2 | Reason for the notification | | |
| a) | Position/status | Board member | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of issuer | | |
| a) | Name | Lytix Biopharma AS | |
| b) | LEI | 549300NXMIMRBCDZO71 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) | |
| b) | Nature of the transaction | Subscription and allocation of shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | NOK 6 | 13,500 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 13,500 Total price: NOK 81,000 | |
| e) | Date of the transaction | 2024-12-16 | |
| f) | Place of the transaction | Outside a trading venue | |

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | |
|----------|--|---|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Saturn Invest AS |
| 2 | Reason for the notification | |
| a) | Position/status | Closely associated person of primary insider Brynjar Forbergskog (board member) |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of issuer | |
| a) | Name | Lytix Biopharma AS |
| b) | LEI | 549300NXMIMRBCDZO71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) |
| b) | Nature of the transaction | Subscription and allocation of shares |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | NOK 6 |
| | | 3,166,666 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 3,166,666 Total price: NOK 18,999,996 |
| e) | Date of the transaction | 2024-12-16 |
| f) | Place of the transaction | Outside a trading venue |

NOTIFICATION BY PRIMARY INSIDERS / CLOSE ASSOCIATE

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Øystein Rekdal |
| 2 | Reason for the notification | |
| a) | Position/status | Managing director |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of issuer | |
| a) | Name | Lytix Biopharma AS |
| b) | LEI | 549300NXMIMRBCDZO71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Shares in Lytix Biopharma AS (ISIN NO 0010405780) |
| b) | Nature of the transaction | Subscription and allocation of shares |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | NOK 6 |
| | | 16,666 |
| d) | Aggregated information — Aggregated volume — Price | Aggregated volume: 16,666 Total price: NOK 99,996 |
| e) | Date of the transaction | 2024-12-16 |
| f) | Place of the transaction | Outside a trading venue |